Chronic Wounds Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 3+ key companies continuously working towards developing 3+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Chronic Wounds Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.

Some of the key takeaways from the Chronic Wounds Pipeline Report: https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chronic Wounds treatment therapies with a considerable amount of success over the years.
• Chronic Wounds companies working in the treatment market are Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others, are developing therapies for the Chronic Wounds treatment
• Emerging Chronic Wounds therapies in the different phases of clinical trials are- ADRCs, ON101, EscharEx, SkinTE, and others are expected to have a significant impact on the Chronic Wounds market in the coming years.
• In July 2025, BioLab Holdings, Inc., a Phoenix-based medical manufacturer focused on wound healing and regenerative therapies, has announced the initiation of a multicenter hybrid platform trial to evaluate the clinical effectiveness of its amnion-based wound care products in patients with difficult-to-treat diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, titled "CAMP RWE Trial: A Multicenter Hybrid Platform Trial Comparing the Effects of a Prospective Cohort Treated With a Tri-Layer Amnion Graft or a Single-Layer Amnion Graft to a Coarsened Exact Matched Retrospective Control Cohort of Patients With Hard-to-Heal DFUs and VLUs," aims to generate real-world evidence (RWE) on the performance of BioLab's Tri-Membrane WrapTM and Membrane Wrap - LiteTM.
• In March 2025, UK-based biotech firm SolasCure initiated the randomized, controlled CLEANVLU2 Phase II trial of its Aurase Wound Gel for chronic wound treatment, enrolling the first patient. The patented biomimetic gel contains Tarumase, an enzyme derived from medical maggots, which aids healing by breaking down fibrin, elastin, and collagen in wounds to promote debridement. CLEANVLU2 builds on findings from the earlier Phase IIa study, which confirmed the product's safety and pain-free application, and will now assess the effectiveness of a higher Tarumase concentration in patients with venous leg ulcers.
• In December 2024, MediWound's first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic designed for eschar removal in deep partial-thickness and full-thickness thermal burns, effectively minimizing the need for surgery. Utilizing its proprietary enzymatic technology, MediWound is also developing EscharEx®, a promising Phase III candidate for chronic wound debridement. Phase II trials have demonstrated EscharEx's notable advantages over the current market leader, valued at over $360 million, positioning it for substantial market expansion.
• In March 2024, SOLASCURE released its Phase IIa clinical trial findings for its CLEANVLU study in the prestigious International Wound Journal. The trial evaluated Aurase Wound Gel, SOLASCURE's initial investigational product. This gel, containing tarumase (provisional INN), a recombinant enzyme derived from medical maggots, is designed to facilitate wound healing by aiding in debridement and preparing the wound bed.
• In February 2024, Cynata Therapeutics Limited finished the preliminary examination of wound area in the initial 16 participants within its phase 1 clinical study of CYP-006TK for diabetic foot ulcers (DFU), up to the 10-week follow-up period.

Chronic Wounds Overview
Chronic wounds are injuries to the skin that fail to progress through the normal stages of healing within an expected timeframe, typically within three months. These wounds often remain open for an extended period, leading to persistent inflammation and delayed healing. Common types of chronic wounds include pressure ulcers, diabetic foot ulcers, venous ulcers, and arterial ulcers.

Get a Free Sample PDF Report to know more about Chronic Wounds Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Chronic Wounds Drugs Under Different Phases of Clinical Development Include:
• ADRCs: Paracrine, Inc
• ON101: Oneness Biotech
• EscharEx: MediWound
• SkinTE: PolarityTE

Chronic Wounds Route of Administration
Chronic Wounds pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chronic Wounds Molecule Type
Chronic Wounds Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Chronic Wounds Pipeline Therapeutics Assessment
• Chronic Wounds Assessment by Product Type
• Chronic Wounds By Stage and Product Type
• Chronic Wounds Assessment by Route of Administration
• Chronic Wounds By Stage and Route of Administration
• Chronic Wounds Assessment by Molecule Type
• Chronic Wounds by Stage and Molecule Type

DelveInsight's Chronic Wounds Report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Wounds product details are provided in the report. Download the Chronic Wounds pipeline report to learn more about the emerging Chronic Wounds therapies
https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Chronic Wounds Therapeutics Market include:
Key companies developing therapies for Chronic Wounds are - ConvaTec Inc., Smith & Nephew, 3M, and others.

Chronic Wounds Pipeline Analysis:
The Chronic Wounds pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Wounds with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Wounds Treatment.
• Chronic Wounds key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Wounds Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Wounds market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Wounds drugs and therapies
https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Wounds Pipeline Market Drivers
• The drivers of the chronic wound care market include factors such as the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune diseases, the growing elderly population, the rise in sports related injuries, and the need for advanced wound care products and treatments.

Chronic Wounds Pipeline Market Barriers
• With a limited patient population, pharmaceutical companies face challenges in recouping the substantial expenses incurred during the research, development, and clinical trial phases of new treatments.

Scope of Chronic Wounds Pipeline Drug Insight
• Coverage: Global
• Key Chronic Wounds Companies: Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others
• Key Chronic Wounds Therapies: ADRCs, ON101, EscharEx, SkinTE, and others
• Chronic Wounds Therapeutic Assessment: Chronic Wounds current marketed and Chronic Wounds emerging therapies
• Chronic Wounds Market Dynamics: Chronic Wounds market drivers and Chronic Wounds market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.